Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

Vincent Planche, Nicolas Villain
JAMA Neurol. 2023-04-24; :
DOI: 10.1001/jamaneurol.2023.0815

Read on PubMed

This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.

Know more about